ArticleCurrent infectious disease reports2013
Endocarditis caused by resistant enterococcus: an overview.
Article in Current infectious disease reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 15 citations in OpenAlex.
- Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in anAntimicrobial agents and chemotherapy · 2020Article
- Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Observational
- Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management.Infection and drug resistance · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enteroccocal infective endocarditis is a major challenge to clinicians. There are an increasing number of reports of nosocomial acquisition and multidrug-resistant strains complicating management. The therapy of choice for enterococcal endocarditis remains ampicillin and gentamicin; however, high levels of aminoglycoside resistance, vancomycin-resistance, and toxicity of gentamicin with prolonged therapy have necessitated the use of other options in some patients. When the combination of cell wall drug and aminoglycoside cannot be used, the optimal regimen is not well established, due to limited information from clinical trials. There is thus an urgent need to better understand pathogenesis, resistance mechanisms, and optimal management strategies. Clinicians need to explore both antimicrobial and nonantimicrobial strategies for management, including evaluation of those at risk, early diagnosis, appropriate combination, and infection prevention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.